On-Demand: A Deep Dive Into the CMC, Technology and Financial Aspects of Successful Development of an Orally Delivered GLP-1
31 October 2024Dr. Andrew Lewis, Chief Scientific Officer, and Dr. Andrew Parker, Senior Drug Development Consultant, explore the drug delivery challenge in this follow-up from the first in our series “Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond”.
Our experts talk through the bioavailability challenge and offer perspectives on how pharma have successfully addressed this through molecule design and optimization of drug product performance through iterative clinical assessment, before describing how the initial GLP-1 therapeutics have stimulated other drug developers to expand into analogous mechanisms of action and small molecule therapeutics.
In this webinar:
- Learn about the biopharmaceutic considerations for oral GLP-1 peptide therapeutics and how industry has innovated to overcome them
- Hear about the health economic considerations of oral peptide delivery
- Get an overview of other developments outside GLP-1 peptides to address the obesity therapeutic area
Watch our on-demand recording and stay at the forefront of treatment advancements in this quickly evolving category.
